Clinical Trials Using Dexamethasone

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dexamethasone. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 126-148 of 148
< Previous 1 ... 4 5 6

  • Daratumumab, Bortezomib, and Dexamethasone with or without Venetoclax in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of venetoclax when given together with daratumumab, bortezomib, and dexamethasone, and how well they work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as venetoclax and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving venetoclax with daratumumab, bortezomib, and dexamethasone may work better in treating patients with relapsed or refractory multiple myeloma compared to standard of care treatment, including chemotherapy.
    Location: 3 locations

  • Palbociclib and Combination Chemotherapy in Treating Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

    This phase I trial studies how well palbociclib and combination chemotherapy work in treating pediatric patients with acute lymphoblastic leukemia that has come back or does not respond to treatment. Palbociclib and dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, bortezomib, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib and combination chemotherapy may work better in treating pediatric patients with acute lymphoblastic leukemia.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 7 locations

  • Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients with Multiple Myeloma Ineligible for Transplant

    This phase I / II trial studies the best dose and side effects of ibrutinib when given together with lenalidomide and dexamethasone and how well they work in treating patients with multiple myeloma that are not eligible for transplant. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: Mayo Clinic in Florida, Jacksonville, Florida

  • R-(-)-Gossypol Acetic Acid with Lenalidomide and Dexamethasone in Treating Patients with Relapsed Symptomatic Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of R-(-)-gossypol acetic acid when given together with lenalidomide and dexamethasone and to see how well it works in treating patients with multiple myeloma, also known as plasma cell myeloma, that has come back after a period of improvement or has gotten worse after treatment. R-(-)-gossypol acetic acid may stop the growth of cancer cells by recognizing certain proteins and stimulating programmed cell death. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving R-(-)-gossypol acetic acid with lenalidomide and dexamethasone may work better in treating patients with multiple myeloma.
    Location: Mayo Clinic in Florida, Jacksonville, Florida

  • HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients with Relapsed Multiple Myeloma

    This phase Ib trial studies the side effects and best dose of histone deacetylase (HDAC) inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with multiple myeloma that has returned after a period of improvement. HDAC inhibitor AR-42 may work to stop cancer growth by blocking an enzyme needed for cell growth. Pomalidomide is a drug used in chemotherapy that works to stop the growth of cancer cells by causing them to die. Giving HDAC inhibitor AR-42 together with pomalidomide may cause patients to respond better to treatment.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Isatuximab and Carfilzomib with or without Dexamethasone and Lenalidomide in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.
    Location: 3 locations

  • Wild-type Reovirus in Combination with Carfilzomib and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This pilot phase I clinical trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A virus called wild-type reovirus may be able to kill cancer cells without damaging normal cells and seems to work best when given with chemotherapy. Giving wild-type reovirus with chemotherapy may be a more effective treatment than chemotherapy alone.
    Location: 3 locations

  • Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

    This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in targeted way and delivers vedotin to kill them. Crizotinib and methotrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether brentuximab vedotin and combination chemotherapy is more effective than crizotinib and combination chemotherapy in treating anaplastic large cell lymphoma.
    Location: 143 locations

  • Olanzapine with or without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

    This phase III trial studies how well olanzapine with or without fosaprepitant dimeglumine works in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine, when given with other drugs, is still effective without using fosaprepitant dimeglumine for controlling nausea and vomiting.
    Location: 435 locations

  • Netupitant / Palonosetron Hydrochloride and Dexamethasone with or without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer

    This randomized phase III trial studies how well netupitant / palonosetron hydrochloride and dexamethasone with or without prochlorperazine or olanzapine work in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
    Location: 335 locations

  • Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients with Cancer

    This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
    Location: 295 locations

  • Dexamethasone in Controlling Dyspnea in Patients with Cancer

    This phase III trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer patients.
    Location: 2 locations

  • Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy with Immediate Reconstruction

    This phase IV trial compares the effects of different injection sites for standard nerve blocks given before double mastectomy with immediate reconstruction. Nerve blocks help with pain relief during surgery and recovery, and they can be given in different areas of the body, including the upper back and / or upper chest area. While nerve blocks are standard of care for this type of surgery, it is not known which nerve block approach helps relieve pain after surgery the most. This trial studies whether one site or a combination of sites is better than the others at decreasing pain during surgery and reducing the need for pain medication after surgery.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Physical Activity with or without Dexamethasone in Reducing Cancer-Related Fatigue in Patients with Locally Advanced, Metastatic, or Recurrent Cancer

    This phase II / III trial studies how well physical activity with or without dexamethasone works in reducing cancer-related fatigue in patients with cancer that has spread to other places in the body or has come back. Dexamethasone may decrease the body’s immune response. Combining physical activity with dexamethasone may help to treat fatigue in patients with cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Aprepitant or Fosaprepitant in Combination with Dexamethasone and Ondansetron in Preventing Nausea and Vomiting in Patients with Cancer Receiving Carboplatin-Based Chemotherapy

    This phase II trial studies how well aprepitant or fosaprepitant in combination with dexamethasone and ondansetron work in preventing nausea and vomiting in patients with cancer receiving carboplatin-based chemotherapy. Giving aprepitant or fosaprepitant in addition to standard anti-nausea medications such as dexamethasone and ondansetron may help control nausea and vomiting better compared to in dexamethasone and ondansetron alone in patients receiving carboplatin-based chemotherapy.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • Caudal Nerve Block in Reducing Post-Operative Pain in Adult Patients Undergoing Penile Prosthesis Surgery

    This randomized phase III trial studies caudal nerve block to see how well it works compared with general anesthesia in reducing post-operative pain in adult patients undergoing penile prosthesis surgery. A caudal nerve block is a local anesthetic injected near the tailbone which may help reduce the level of pain and length of hospital stay after surgery.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Rolapitant Hydrochloride in Preventing Nausea / Vomiting in Patients with Sarcoma Receiving Chemotherapy

    This randomized phase II trial studies how well rolapitant hydrochloride works in preventing nausea / vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated with chemotherapy.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

    The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Whole Body-MRI or PET Scan and Image-Guided Biopsy in Assessing Response in Participants with Multiple Myeloma Receiving Carfilzomib, Lenalidomide, and Dexamethasone

    This phase II trial studies how well whole body-magnetic resonance imaging (WB-MRI) or positron emission tomography (PET) and image-guided biopsy work in assessing response in participants with multiple myeloma receiving carfilzomib, lenalidomide, and dexamethasone. Diagnostic procedures, such as MRI and PET, may help measure a participant's response to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. WB-MRI or PET and image-guided biopsy may improve response assessment strategy after chemotherapy in participants with multiple myeloma.
    Location: Yale University, New Haven, Connecticut

  • Dexamethasone Effects in Patients with Newly Diagnosed, Recurrent, or Progressive Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

    This pilot phase II trial studies the effects of dexamethasone in patients with non-small cell lung cancer that is newly diagnosed, has come back, or is growing, spreading, or getting worse. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography, use a small amount of radioactive substance to show changes in tumor cells. Studying the effects of dexamethasone on lung tumors using FLT positron emission tomography may help doctors plan better treatments.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed / Refractory (r / r) Multiple Myeloma (MM)

    The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r / r MM.
    Location: 5 locations

  • A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

    The purpose of this study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen.
    Location: 2 locations


< Previous 1 ... 4 5 6